Expand all sections

Alpha-1 antitrypsin

Glassia

Extended indication Alpha-1 antitrypsin deficiency (AATD); inhaled therapy for emphysema.
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Alpha-1 antitrypsin
Domain Lung diseases
Main indication Lung other
Extended indication Alpha-1 antitrypsin deficiency (AATD); inhaled therapy for emphysema.
Proprietary name Glassia
Manufacturer kamada
Additional remarks Kamada heeft de registratieaanvraag teruggetrokken in juni 2017. De EMA heeft aangegeven dat de huidige aanvraag niet voldoende onderbouwd is voor toelating.

Registration

Particularity New therapeutical formulation
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.